RxDoctor Payments DataLook up a doctor →

Daniel Wildes, DO

Cardiovascular Disease · Tulsa, OKNPI 1932163565

Payments from drug & device makers

$24,088in general payments, 2019–2025

Across 618 payments — averaging $38.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$4K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
  • Abbott$3K
  • Boston Scientific$3K
  • Novartis$2K
  • Philips North America LLC$1K
  • plus $8K from 43 others

What the payments were for

  • Speaking & faculty fees$3,00012%
  • Travel & lodging$4502%
  • Food & beverage$20,59886%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,088 in reported general payments places this provider in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$99,896
Medicare patients
584
Services billed
1,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$124,973
EntrestoSacubitril/Valsartan105$96,140
MultaqDronedarone Hcl24$20,229
BrilintaTicagrelor18$12,380
JardianceEmpagliflozin11$11,991
FarxigaDapagliflozin Propanediol14$7,341
VerquvoVericiguat12$7,145
Repatha SyringeEvolocumab13$6,902
Metoprolol Succinate204$1,990
Atorvastatin Calcium100$978
Ezetimibe60$814
Valsartan23$736
Ezetimibe-SimvastatinEzetimibe/Simvastatin11$625
Carvedilol123$614
Chlorthalidone57$605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$504$124,973138 claims
NovartisEntresto$1,652$96,140105 claims
Sanofi-aventis U.S. LLCMultaq$18$20,22924 claims
AstraZenecaBrilinta, Farxiga$325$19,72132 claims
Boehringer IngelheimJardiance$141$11,99111 claims
MerckVerquvo$542$7,14512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →